Core Symptoms Sapropterin Improves in PKU
Sapropterin dihydrochloride (Kuvan) reduces blood phenylalanine (Phe) levels in phenylketonuria (PKU) patients responsive to the drug, addressing the primary biochemical defect. This leads to improved Phe tolerance, allowing higher protein intake without hyperphenylalaninemia.[1]
Which Patients See Symptom Improvement?
Only about 20-30% of PKU patients are sapropterin responders, determined by a Phe reduction of at least 30% after an 8-day trial. Responders show:
- Lower fasting Phe levels.
- Better dietary control, reducing food restrictions.[1][2]
Non-responders see no benefit, as sapropterin enhances phenylalanine hydroxylase (PAH) activity only in specific genetic variants (e.g., BH4-responsive mutations).[2]
Neurocognitive Improvements Linked to Treatment
Lowering Phe improves brain function in responsive patients:
- Enhanced executive function, attention, and processing speed in children and adults.
- Better IQ scores and behavioral outcomes with long-term use (e.g., 6-10 years).
- Reduced white matter abnormalities on MRI, correlating with cognitive gains.[3][4]
Studies show treated children gain 7-11 IQ points versus diet-alone controls.[3]
What Symptoms Don't Improve?
Sapropterin does not reverse existing neurological damage from prior untreated PKU, such as severe intellectual disability or seizures. It works best started early or in mild/moderate PKU.[1][2]
How Quickly Do Improvements Appear?
Phe levels drop within hours to days in responders; neurocognitive benefits emerge over months to years with sustained treatment.[4]
Sources
[1]: FDA Label for Kuvan
[2]: DrugPatentWatch.com - Sapropterin Patents
[3]: NEJM Study on Sapropterin in PKU
[4]: Long-term PKU Outcomes Review